

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>A61K 31/44, 31/415, 31/53, 31/55, 31/165, 31/425</b>	<b>A2</b>	(11) International Publication Number: <b>WO 94/18972</b>  (43) International Publication Date: <b>1 September 1994 (01.09.94)</b>
(21) International Application Number: <b>PCT/US94/01788</b>  (22) International Filing Date: <b>17 February 1994 (17.02.94)</b>  (30) Priority Data: <b>08/023,016                      25 February 1993 (25.02.93)      US</b>  (71) Applicant: <b>WARNER-LAMBERT COMPANY [US/US]; 2800 Plymouth Road, Ann Arbor, MI 48105 (US).</b>  (72) Inventors: <b>TAYLOR, Charles, Price, Jr.; 7560 Lake Shore Drive, Chelsea, MI 48118 (US). WEBER, Mark, Lawrence; 24678 Farmington Road, Farmington Hills, MI 48336 (US).</b>  (74) Agents: <b>ASHBROOK, Charles, W.; Warner-Lambert Com- pany, 2800 Plymouth Road, Ann Arbor, MI 48105 (US) et al.</b>		(81) Designated States: <b>AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b>  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: <b>METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS USING N-(2,6-DISUBSTITUTED AROMATIC)-N'-PYRIDINYL UREAS AND OTHER ANTICONVULSANT COMPOUNDS</b>		
(57) Abstract  The instant invention is novel uses of known N-(2,6-disubstituted phenyl)-N'-3- and 4-pyridinyl ureas and pharmaceutically acceptable acid addition salts thereof. Such compounds as N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea monohydrochloride or N-(2,3-dichlorophenyl)-N'-4-pyridinyl urea are used for treating neurodegenerative disorders, perinatal asphyxia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. The instant invention is similar novel uses of known anticonvulsant compounds as ralitoline, phenytoin, lamotrigine, tetrodotoxin, lidocaine, and carbamazepine.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

METHODS FOR TREATING NEURODEGENERATIVE  
DISEASES AND DISORDERS USING  
N-(2,6-DISUBSTITUTED AROMATIC)-N'-PYRIDINYL UREAS  
AND OTHER ANTICONVULSANT COMPOUNDS

5

BACKGROUND OF THE INVENTION

The present invention relates to novel therapeutic  
uses of a known compound, N-(2,6-disubstituted  
10 aromatic)-N'-pyridinyl ureas, its derivatives, and  
pharmaceutically acceptable salts. The present  
invention also relates to novel therapeutic uses of  
various other anticonvulsant drugs, their derivatives,  
and pharmaceutically acceptable salts. The present  
15 invention concerns a method for treating  
neurodegenerative diseases and disorders in a mammal in  
need of such treatment.

Such neurodegenerative diseases are, for example,  
Alzheimer's disease, Huntington's disease, Parkinson's  
20 disease, and Amyotrophic Lateral Sclerosis.

The present invention also covers treating  
neurodegenerative disorders termed acute brain injury.  
These include but are not limited to: stroke, head  
trauma, and asphyxia.

25 Stroke refers to a cerebral vascular disease and  
may also be referred to as a cerebral vascular  
incidence (CVA) and includes acute thromboembolic  
stroke. Stroke includes both focal and global  
ischemia. Also included are transient cerebral  
30 ischemic attacks and other cerebrovascular problems  
accompanied by cerebral ischemia. A patient undergoing  
carotid endarterectomy specifically or other  
cerebrovascular or vascular surgical procedures in  
general, or diagnostic vascular procedures including  
35 cerebral angiography and the like.

Other incidents are head trauma, spinal cord  
trauma, or injury from general anoxia, hypoxia,

-2-

hypoglycemia, hypotension as well as similar injuries seen during procedures from embole, hyperfusion, and hypoxia.

5       The instant invention would be useful in a range of incidents, for example, during cardiac bypass surgery, in incidents of intracranial hemorrhage, in perinatal asphyxia, in cardiac arrest, and status epilepticus.

10       A skilled physician will be able to determine the appropriate situation in which subjects are susceptible to or at risk of, for example, stroke as well as those suffering from stroke for administration by methods of the present invention.

15       After ischemia of the brain in vivo many changes take place. There is a rapid loss of synaptic activity, a large shift in extracellular voltage, a release of the neurotransmitter glutamate, and a loss of ion homeostasis. The excess release of glutamate may be especially important in ischemic injury.

20       Glutamate is an excitotoxin, meaning that overstimulation of glutamate receptor-linked channels allows excess calcium and sodium influx into neurons leading to neuronal death.

25       The overstimulation of receptors is thought to be involved in the etiology of several neurological disorders, i.e., epilepsy and cerebral ischemia. Evidence is also accumulating that the brain damage associated with anoxia, stroke, hypoglycemia, epilepsy, and perhaps neurodegenerative illnesses such as

30       Alzheimer's or Huntington's diseases may be at least partially produced by excessive activation of N-methyl-D-aspartic acid (NMDA) receptors (Kemp JA, Foster AC, Wong BHF, Trends in Neurosciences 1987;10(7):294-8).

35       The present invention employs the use of anticonvulsant compounds, such as the compounds of Formula I which are phenyl pyridinyl ureas as a method

- 3 -

of blocking or delaying damage to neurons from conditions similar to ischemia. It is believed that by preventing neuronal damage, the compounds of Formula I, alone or together with a pharmaceutically acceptable carrier, can be used to treat neurological diseases such as Alzheimer's disease, Huntington's disease, Parkinson's disease, myotrophic lateral sclerosis, and disorders such as stroke, head trauma, and asphyxia. The present invention is also directed to similar uses and methods of treatment employing other anticonvulsant compounds disclosed herein.

Various substituted phenyl pyridinyl ureas have been described but none having neuroprotective activity. For example, Bruce MI, Zwar JA, Proc Roy Soc (London), Sec. B. 165 (1999), 1966;245-65 disclose many N-mono- and N,N'-disubstituted ureas having cytokinin activity. N-(3,4-dichlorophenyl)-N'-3- and 4-pyridinyl ureas show such activity whereas the corresponding 2,5-dichloro compounds were inactive. In general, the authors concluded that phenyl ring substitution enhanced activity with meta substituents providing highest activity and ortho substituents lowest activity.

German Patent Publication 2,928,485 also describes various ureas including N-(3-chloro-4-trifluoromethyl-phenyl)-N'-3- and 4-pyridinyl ureas as being useful for inhibiting lipid absorption.

French Patent Publication 2,155,856 teaches various 2-pyridinyl ureas including N-(3,4-dichlorophenyl)-N'-2-pyridinyl urea as having antiinflammatory and analgesic activity.

U.S. Patent Number 4,629,731 covers the phenyl pyridinyl urea compounds of the instant invention, methods for preparing them, and their use as an anticonvulsant. The term convulsions is intended to mean the characteristic body movements which are associated with the group of chronic central nervous


- 4 -

system disorders termed epilepsies. The patent is hereby incorporated by reference.

There is no disclosure in the above references to suggest the present invention's novel uses of compounds of U.S. Patent Number 4,629,731 to treat neurodegenerative diseases and disorders in a mammal in need of such treatment.

### SUMMARY OF THE INVENTION

The present invention relates to novel uses of anticonvulsant compounds such as the known compounds of the formula



I

wherein A is 3- or 4-pyridinyl; R<sub>1</sub> and R<sub>2</sub> are each independently halogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkoxycarbonyl, or nitro, and R<sub>3</sub> is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkanoyl, lower alkoxycarbonyl, or nitro, or a pharmaceutically acceptable acid addition salt thereof.

The present invention also relates to novel uses of various other anticonvulsant compounds such as ralitoline, phenytoin, lamotrigine, tetrodotoxin, lidocaine, and carbamazepine.

The present invention further includes novel uses of a pharmaceutical composition comprising a neuroprotective effective amount of a compound of Formula I or other anticonvulsant compounds together with a pharmaceutically acceptable carrier.

- 5 -

The novel uses of the instant invention concerns a method for treating neurodegenerative diseases or disorders in mammals suffering therefrom by administering to such mammals a neuroprotective effective amount of a compound of Formula I or the additionally disclosed anticonvulsants, or a compound of Formula I or the additionally disclosed anticonvulsants together with a pharmaceutically acceptable carrier, in unit dosage form.

#### Brief Description of the Drawings

Figure 1 are graphs reporting oxygen-tension measurements made with an oxygen-sensitive microelectrode in Example 3.

Figure 2 is a graph reporting that the percentage of slices that recovered at least half of their Prehypoxic-Hypoglycemic Synaptic Potential Amplitude increased with increasing concentrations of a compound of Formula I.

Figure 3 are graphs of the mean EPSP Amplitudes at the end of the experiments conducted in Example 3.

Figure 4 is a graph indicating that the percentage of slices that recovered at least half of their Prehypoxic-Hypoglycemic Synaptic Potential Amplitude varied with drug treatments.

#### DETAILED DESCRIPTION OF THE EMBODIMENTS

The term "halogen" as used herein in the definition of the compounds of the Formula I includes fluorine, chlorine, bromine, and iodine.

The term "lower" in reference to alkyl, alkoxy, alkanoyl, and alkoxycarbonyl pertains to a straight or branched carbon chain of from 1 to 4 carbon atoms, such as methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, or t-butyl.

- 6 -

The compounds of structural Formula I are basic in nature and form pharmaceutically acceptable salts with both organic and inorganic acids. Examples of such acids are acetic, hydrochloric, phosphoric, nitric, sulfuric, fumaric, citric, maleic, malic, and the like. The salts are prepared by contacting the free base form of the pyridinyl-urea with an equivalent amount of the desired acid in the conventional manner. The free base forms may be regenerated by treating the salt form with a base. For example, dilute aqueous basic solutions may be utilized. Dilute aqueous sodium hydroxide, sodium carbonate, or ammonia are suitable for this purpose. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but the salts are otherwise equivalent to their respective free base forms for purposes of the invention.

The compounds of the invention of Formula I can exist in unsolvated as well as solvated forms, including hydrated forms. In general, the solvated forms, with pharmaceutically acceptable solvents such as water, ethanol, and the like are equivalent to the unsolvated forms for purposes of the invention.

A preferred embodiment of the compound of the Formula I employed as a neuroprotective agent is where  $R_3$  is hydrogen or a pharmaceutically acceptable acid addition salt thereof.

Another preferred embodiment of the compound of the Formula I is where  $R_1$  and  $R_2$  are each independently halogen or lower alkyl, or a pharmaceutically acceptable acid addition salt thereof.

Still another preferred embodiment of the compound of Formula I is where  $R_1$  and  $R_2$  are each independently chlorine or methyl.

Particular embodiments are the following compounds:

- 7 -

N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea monohydrochloride;

N-(2,3-dichlorophenyl)-N'-4-pyridinyl urea;

N-(2,6-dichlorophenyl)-N'-4-pyridinyl urea;

5 N-(2,6-dichlorophenyl)-N'-3-pyridinyl urea;

N-(2,6-dimethylphenyl)-N'-4-pyridinyl urea;

N-(2,6-dimethylphenyl)-N'-3-pyridinyl urea;

N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea;

N-(2-chloro-6-methylphenyl)-N'-3-pyridinyl urea;

10 N-(2,6-diethylphenyl)-N'-4-pyridinyl urea;

N-(2,6-diethylphenyl)-N'-3-pyridinyl urea;

N-(2,6-dimethyl-4-bromophenyl)-N'-4-pyridinyl

urea;

N-(2,6-dimethyl-4-bromophenyl)-N'-3-pyridinyl

15 urea;

N-(2,4,6-trimethylphenyl)-N'-4-pyridinyl urea;

N-(2,4,6-trimethylphenyl)-N'-3-pyridinyl urea;


N-(2,4,6-trichlorophenyl)-N'-4-pyridinyl urea;

N-(2,4,6-trichlorophenyl)-N'-3-pyridinyl urea;

20 or a pharmaceutically acceptable acid addition salt thereof.

The compounds of Formula I may be prepared by reacting an isocyanate of the formula

25



II

30

with an equimolar amount of 3- or 4-aminopyridine in an inert solvent, such as tetrahydrofuran, dioxane, and the like, at elevated temperatures, such as at the boiling point of the solvent used.

35

The starting materials such as the various isocyanates are known and can be purchased commercially or synthesized by known methods.

- 8 -

The additional compounds, which are anticonvulsant compounds and can be used as agents for treating neurogenerative diseases or disorders as heretofore discussed, include ralitoline, phenytoin, lamotrigine, tetrodotoxin, lidocaine, and carbamazepine. The methods for making and administering each of these compounds are known to those skilled in the art and can be shown respectively by reference to the following publications: European Patent 124,911, U.S. Patents 2,409,754 and 4,602,017, Kishi et al, Am Chem Soc 1972;94:9219, U.S. Patents 2,441,498 and 2,948,718. As it will be illustrated at a later point, each of these compounds have been shown in vitro to have neuroprotective capabilities.

It should be understood that the present invention is not limited to the use of the anticonvulsant compounds disclosed herein. Similar compounds which prevent irreversible neuronal damage from conditions similar to ischemia are also included in the present invention. In addition, anticonvulsant compounds that bind to sodium channels or that cause a voltage-dependent block to sodium currents or that modulate ion channels without simply blocking them are also included in the present invention.

The compounds of structural Formula I, and the additionally disclosed anticonvulsant compounds, can be prepared and administered in a wide variety of oral and parenteral dosage forms. The compounds of structural Formula I or the other disclosed anticonvulsant compounds can also be administered intravenously. For example, a useful oral dosage is between 50 and 5000 mg, a useful parenteral dosage is between 50 and 2000 mg, and a useful intravenous dosage is between 10 and 1000 mg.

For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either

- 9 -

solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active compounds of the present invention. In the tablet the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5% to 10% to about 70% of the active ingredient. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it. Similarly, cachets are included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form preparations include solutions, suspensions, and emulsions. As an example, water or water-propylene glycol solutions may be mentioned for parenteral injections. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the

-10-

finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other well-known suspending agents. Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself or it can be the appropriate number of any of these in packaged form.

The quantity of active compound in a unit dose of preparation may be varied or adjusted from 10 mg to 1000 mg according to the particular application and the potency of the active ingredient.

In therapeutic use as agents for treating neurodegenerative diseases or disorders, the compounds utilized in the pharmaceutical methods of this invention are administered at the initial dosage of about 1 mg/kg to about 30 mg/kg daily. A daily dose range of about 3 mg/kg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for the particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

- 11 -

The advantages of using the compounds of the instant invention include the relatively nontoxic nature of the compound, the ease of preparation, the fact that the compound is well tolerated, and the ease of administration of the drug.

The following nonlimiting examples illustrate the preferred methods for preparing and using the compounds of the invention.

## EXAMPLE 1

N-(2,6-Dichlorophenyl)-N'-4-pyridinyl urea

A solution of 4.7 g (0.05 mol) of 4-aminopyridine in 300 mL of anhydrous tetrahydrofuran was treated with 9.4 g (0.05 mol) of 2,6-dichlorophenylisocyanate. The solution was heated at reflux for 24 hours, cooled, and concentrated in vacuo to a solid. Recrystallization from aqueous ethanol afforded the crystalline product, mp 217-219°C.

## EXAMPLE 2

In a similar manner as described in Example 1, the following compounds were prepared by reacting the appropriate isocyanate with 3- or 4-aminopyridine:

N-(2,6-dichlorophenyl)-N'-3-pyridinyl urea,  
mp 225-227°C;

N-(2,6-dimethylphenyl)-N'-3-pyridinyl urea,  
mp 190-192°C;

N-(2,6-dimethylphenyl)-N'-4-pyridinyl urea,  
mp 187-188°C;

N-(2,6-diethylphenyl)-N'-3-pyridinyl urea,  
mp 196-197°C;

N-(2,6-diethylphenyl)-N'-4-pyridinyl urea,  
mp 178-180°C;

N-(2-chloro-6-methylphenyl)-N'-3-pyridinyl urea,  
mp 246-247°C; and

N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea,  
mp 210-212°C.

- 12 -

## EXAMPLE 3

An in vitro model with rat hippocampal brain slices exposed to hypoxia-hypoglycemia was used to simulate ischemia. Neuroprotection was measured by the recovery of excitatory postsynaptic potentials after reoxygenation.

Oxygen tension was measured in superfusing solution and in slice tissue using polarized glass-insulated carbon fiber electrodes according to the methods of Jiang, et al (Brain Res 1991;568:159-64). The polarographic potential was -750 mV and the carbon fiber sensing element was 8  $\mu$ m in diameter.

Young male Wistar rats (150 to 250 g) were anesthetized with ketamine (200 mg/kg IP) and ether and were perfused transcardially with cold, oxygenated, low sodium-containing physiological buffer solution (252 mM sucrose, 3.5 mM KCl, 1.0 mM  $\text{MgSO}_4$ , 20 mM  $\text{CaCl}_2$ , 26 mM  $\text{NaHCO}_3$ , 1.25 mM  $\text{NaH}_2\text{PO}_4$ , and 10 mM glucose) with 50  $\mu$ M ketamine added. Brains were removed and hippocampi carefully excised. Hippocampi were sliced transversely at 450  $\mu$ m and transferred into cold (4°C) low-sodium buffer solution gassed with 95%  $\text{O}_2$ , 5%  $\text{CO}_2$  at 31°C. After 45 minutes slices were transferred to oxygenated normal physiological solution (126 mM NaCl, 3.5 mM KCl, 1.0 mM  $\text{MgSO}_4$ , 2.0 mM  $\text{CaCl}_2$ , 20 mM  $\text{NaHCO}_3$ , 1.25 mM  $\text{NaH}_2\text{PO}_4$ , and 10 mM glucose) at 31°C for at least 1 hour before experiments began. After preincubation, slices were transferred to a heated (36°C), gassed incubation chamber where they were continuously superfused with gassed normal physiological solution. Evoked extracellular synaptic potentials (EPSPs) were obtained using glass micropipettes placed approximately 100  $\mu$ m into the slice. Electrical stimulation was applied once per minute to the stratum radiatum by insulated paired nichrome wires (60  $\mu$ m diameter). Stimuli consisted of

-13-

150  $\mu$ A pulses lasting 0.4 msec. The 150  $\mu$ A stimulus usually gave nearly a maximal EPSP (excitatory postsynaptic potential) amplitude. Data from a slice were used only if EPSP amplitude was greater than 2.0 mV before hypoxia-hypoglycemia.

Evoked potentials were recorded and analyzed with a digital computer interface. Experiments were started by recording for several minutes under normal conditions (95%  $O_2$ , 5%  $CO_2$ , 10 mM glucose). Then drug was added to the superfusion solution (or normal solution was continued in control experiments). After 10 minutes of drug superfusion, hypoxia-hypoglycemia was induced by switching to superfusion solution containing added drug with low glucose (2 mM) that was equilibrated with 95%  $N_2$  and 5%  $CO_2$ . At the same time the slice chamber gas was switched to 95%  $N_2$  and 5%  $CO_2$ . Hypoxia-hypoglycemia was continued for 12 minutes. After 12 minutes, 95%  $O_2$  and 10 mM glucose were returned to the slices and the superfusing solution. Following 15 minutes of reoxygenation, the experiment was ended. EPSPs were considered recovered if they returned to at least half of their original amplitude. The percentage of slices with recovered EPSPs were calculated for each condition.

25

#### Oxygen-Tension Measurements

Oxygen tension was measured in medium flowing through the experimental chamber. When the medium, as well as the gas within the chamber was switched from 95% oxygen to 95% nitrogen (carbon dioxide constant at 5%). Results in Figure 1A show that oxygen tension decreased from 95% to approximately 20% of saturation within 1 minute and then reached a plateau of approximately 5% after 4 minutes. Recovery of oxygen tension in the medium upon reoxygenation was rapid, with complete recovery within 30 to 40 seconds.

-14-

Oxygen tension was also measured approximately 100  $\mu$ m deep within hippocampal slice tissue, a depth similar to that used for microelectrode voltage recordings. In stratum pyramidale, oxygen tension under resting conditions was 50% to 65% of saturation as shown in Figure 1B. Oxygen tension in tissue is lower than in bathing medium, presumably because of oxygen utilization by the tissue in agreement with previous studies. After switching to hypoxic medium, oxygen tension in tissue decreased more rapidly and completely than in superfusate, reaching less than 4% of saturation within 1 minute and falling to undetectable low levels within 2 minutes. Despite the rapid fall in oxygen tension, synaptic potentials and population spikes in the CA1 cell body area were seen for at least 3.5 minutes after the start of hypoxia (a typical result in these experiments). Oxygenated medium was reapplied 9 minutes after the start of hypoxia. Oxygen tension in tissue returned to approximately 75% of saturation over 4 to 5 minutes and then finally reached a resting level of approximately 55%. In this experiment as in many others without drug treatment, synaptic potentials never returned following more than 20 minutes of reoxygenation (see below). The time course and extent of changes in tissue oxygen tension were similar in two other experiments with a shorter duration of hypoxia that allowed complete recovery of synaptic potentials (data not shown).

### 30 Synaptic Potential Measurement

Excitatory synaptic potential (EPSP) amplitude was measured before and during drug treatment in the 10-minute period preceding reduced oxygen and glucose. None of the drug treatments altered synaptic potentials before hypoxia (data not shown). Without addition of drug (in control experiments), reduction of oxygen and

-15-

glucose caused a rapid loss of synaptic potentials in each of 20 slices.

5      TABLE 1. Table Shows Effects of Different Concentrations of N-(2-chloro-6-methyl-phenyl)-N'-4-pyridinyl Urea on Recovery of Synaptic Activity (EPSP) in Hippocampal Slices After Hypoxia-hypoglycemia

10	Compound Tested	Concentration ( $\mu$ M)	Number Slices Recovered <sup>b</sup> / Number Slices Tested	p-Value vs Control <sup>a</sup>
	Controls	--	1/20	--
	Test drug	0.5	0/8	NS
	Test drug	2	3/8	0.058
15	Test drug	20	9/10*	<0.00001

\* Significantly different than controls (p < 0.05)

NS = Not significantly different than controls (p > 0.1)

20      <sup>a</sup> p-Value by Fisher's exact test (two-tailed) compared to controls

<sup>b</sup> Slices with  $\geq 50\%$  EPSP amplitude recovery after reoxygenation

25

After 12 minutes of reduced oxygen and glucose and 15 minutes of recovery, EPSP amplitude was measured again. EPSP amplitude was scored as recovered if more than half of the initial value was recorded. Table 1 and Figure 2 show that treatment with N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea increased the percentage of slices that recovered EPSPs from approximately 5% (control) to 37% at 2  $\mu$ M and 90% at a concentration of 20  $\mu$ M (p < 0.00001 by Fisher's exact test).

35

In Figure 2, drug concentrations are listed below each column. The 20  $\mu$ M concentration of N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea gave almost complete protection from loss of EPSPs. [20  $\mu$ M concentration—p < 0.01 compared to control slices by

40

-16-

Fisher's exact test (two-tailed); 2  $\mu$ M concentration—p <0.05].

In addition to increasing the number of slices that reached a 50% criterion for recovery of EPSPs, treatment with N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea significantly increased the mean EPSP amplitude after hypoxia as a percentage of the control. This was also a concentration-related effect that was near significance at a concentration of 2  $\mu$ M and was significant with a high degree of confidence at 20  $\mu$ M.

In Figure 3, use of N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea increased EPSP amplitude following hypoxia in a concentration-dependent manner. Standard error of the mean and p-values for significance compared to controls for concentrations at 2  $\mu$ M and 20  $\mu$ M were as follows (Student's two-tailed t-test): 2  $\mu$ M—p  $\leq$ 0.07; 20  $\mu$ M—p  $\leq$ 0.0002. As indicated in the graph, the use of 20  $\mu$ M of N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea caused an almost complete recovery of EPSPs.

Treatment with 0.5  $\mu$ M of N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea resulted in changes from hypoxia that were not different from control treatments with no drug present.

Treatment with the two higher concentrations of N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea provides significant protection of hippocampal slices from irreversible loss of synaptic potentials after brief application of conditions that mimic ischemia in vitro. Previous studies (Rock DM, McLean MJ, Macdonald RL, et al, Epilepsy Res 1991;8:197-203) show that N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea modulates voltage-dependent sodium channels of nerve cell membranes, and the inventors have determined that this modulation provides protection from hypoxia. A previous study with slices also shows that tetrodotoxin, a very selective sodium channel blocker,

-17-

delays negative shifts from hypoxia. Also, phenytoin, another anticonvulsant, has shown effects preventing neuronal damage from ischemia both in vitro and in vivo. The results showed that treatment with N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea improves recovery of EPSPs at both 2  $\mu$ M and 20  $\mu$ M with the 20  $\mu$ M concentration giving almost complete protection (9 out of 10 slices recovered).

N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea is a modulator of neuronal voltage-gated sodium ion channels. However, it is important to point out that none of the concentrations tested reduced EPSP or presynaptic action potential amplitude. Thus, neuroprotection was obtained by modulating ion channels without simply blocking them. These results suggest that neuroprotection in vivo might be obtained at drug doses that would not greatly alter normal neuronal function.

Although the results with irreversible loss of EPSPs do not directly demonstrate that the test drug prevents ischemic neuronal cell loss, this hypothesis can be tested using histological or biochemical techniques. One hypothesis for the neuroprotective action of this compound is that it blocks neuronal hyperactivity or reduces sodium influx (by modulating sodium channels) and therefore reduces energy demand and preserves ion homeostasis, preventing depolarization similar to that of spreading depression. A similar hypothesis has been advanced for the protection of white matter from hypoxic injury by local anesthetic compounds. Also, a recent report suggests that prevention of spreading depression-like events in vivo underlie the action of certain drugs that prevent tissue infarction from focal ischemia in rats (Gill, et al, J Neuro 1992;67:236-40).

-18-

In conclusion, this study provides evidence that the test drug or similar sodium ion channel modulating drugs prevent neuronal damage from ischemia.

5

## EXAMPLE 4

This study was identical in design to Example 3 except that during the hypoxic period of 12 minutes, glucose was reduced from 10 mM to 2 mM rather than from 10 mM to zero as in Example 3.

10

Synaptic Potential Measurement

15

Without addition of drugs, hypoxia/hypoglycemia caused a rapid loss of synaptic potentials in each of 36 control slices. None of the drug treatments altered synaptic potentials at the concentrations used (data not shown). However, lidocaine reversibly reduced both presynaptic action potential and EPSPs at a concentration of 500  $\mu$ M (data not shown).

-19-

TABLE 2. Table Shows Effects of the Drugs Known to Interact With Voltage-dependent Sodium Channels on Recovery of Synaptic Activity (EPSP) in Hippocampal Slices After Hypoxia-hypoglycemia

Compound Tested	Concentration ( $\mu$ M)	Number Slices Recovered <sup>a</sup> / Number Slices Tested	p-Value vs Control <sup>b</sup>
Controls	--	0/36	--
Phenytoin	5	0/8 (NS)	>0.1
Phenytoin	20	5/12*	0.0005
Phenytoin	50	3/9*	0.0059
Carbamazepine	20	2/9*	0.036
Carbamazepine	50	4/10*	0.0013
Lidocaine	50	5/9*	0.0001
Lidocaine	200	9/10*	<0.00001
Verapamil	1.0	3/8*	0.0042
Verapamil	10	5/9*	0.0001
Nimodipine	1.0	1/9 (NS)	>0.1

<sup>a</sup> Slices with  $\geq$ 50% EPSP amplitude recovery after reoxygenation

<sup>b</sup> p-Value by Fisher's exact test (two-tailed) compared to controls

\* Significantly different than controls (p < 0.05)

NS = Not significantly different than controls (p > 0.1)

Table 2 summarizes data obtained with drug treatments. Seven to 20 slices were recorded in each drug condition and 36 control slices were studied interspersed from time to time over the 4-month period of experiments.

Drug treatment enhanced recovery of EPSPs (especially with lidocaine, phenytoin, and verapamil). Figure 4 shows the significance of EPSP recovery for drug treatment in comparison to controls.

Standard error of the mean p-values for significance compared to controls for the following were found (students' two-tailed t-test):

20  $\mu$ M phenytoin-p < 0.01

50  $\mu$ M phenytoin-p < 0.01

50  $\mu$ M carbamazepine-p < 0.01

50  $\mu$ M lidocaine-p < 0.01

-20-

200  $\mu$ M lidocaine-p <0.0120  $\mu$ M carbamazepine-p <0.05

Drug intervention with four of the five drugs during hypoxia-hypoglycemia provides significant neuroprotection. All four drugs modulate sodium channels. A previous study with slices also shows that tetrodotoxin, a very selective sodium channel blocker, delays loss of ion homeostasis from hypoxia. Results with phenytoin are similar to those with other models of ischemia in vitro and in vivo with models of focal ischemia and global ischemia. Lidocaine treatment improves recovery of EPSPs at both concentrations tested, with 200  $\mu$ M concentration giving almost complete protection (9/10 slices recovered). Although the use of lidocaine for ischemia in vivo is limited by its peripheral hypotensive effects, one study reports that brain damage from global ischemia in rabbits is reduced by lidocaine and another recent study reports neuroprotection by local anesthetics in a model of white matter ischemia.

Each of the drugs in our study are modulators of neuronal voltage-gated ion channels. However, it is important to point out that none of the drugs reduced EPSP or presynaptic action potential amplitude at the concentrations used. Thus, neuroprotection was obtained by modulating ion channels without simply blocking them. These results suggest that neuroprotection in vivo might be obtained at drug doses that would not greatly alter normal neuronal function.

Several of these agents modulate calcium channels as well as sodium channels. Phenytoin blocks a variety of calcium channels at concentrations similar to those tested here while carbamazepine and lidocaine are thought to be more selective for sodium channels. In addition to modulating sodium channels, verapamil is a widely studied blocker of L-type calcium channels. However, verapamil prevented ischemic damage at 10  $\mu$ M

-21-

but not at 1  $\mu$ M. The 10  $\mu$ M concentration is supermaximal for blocking L-type channels but is near the threshold for sodium channel. These results suggest that the neuroprotective action of verapamil is caused by action at sodium channels and not calcium channels. This notion also is supported by results with 1  $\mu$ M nimodipine which failed to prevent loss of EPSPs (nimodipine interacts with sodium channels at concentrations greater than 10  $\mu$ M). Tetrodotoxin, a highly selective blocker of neuronal sodium channels, previously has been reported to reduce neuronal damage from global ischemia.

Although the results with irreversible loss of EPSPs do not directly demonstrate that sodium channel modulators prevent ischemic neuronal cell loss, this hypothesis can be tested using histological techniques. One hypothesis for the neuroprotective action of these compounds is that they block neuronal hyperactivity or reduce sodium influx (by modulating sodium channels) and therefore reduce energy demand and preserve ion homeostasis.

In conclusion, this study provides evidence that these or similar ion channel modulating drugs prevent neuronal damage from ischemia.

25

#### EXAMPLE 5

An assay was conducted to compare the inhibitory action of various compounds which are the subject of the present invention. The assay measured the oxygen deprivation-induced neuronal cell death from various cortical cultures. The results of the assay are provided in Table 3. Lactate dehydrogenase (LDH) is a cytosolic enzyme that is only present in the extracellular medium if cell membranes rupture, indicating cell death. Therefore, LDH release into the culture medium is a convenient assay of cell death. The results of Table 3 indicate that each of the

- 22 -

compounds tested decreased neuronal cell death from hypoxia in vitro. These results suggest that each of the compounds reduce damage from brain ischemia, stroke, or neurodegenerative diseases.

5

#### Primary Culture Preparation

The uteri of Sprague Dawley rats in their 18th day of fetal gestation were removed under halothane anesthesia and placed in a chilled bath of magnesium and calcium-free Hank's balanced salt solution (HBSS). Cortical brain hemispheres were removed from individual fetuses and digested in 0.1% trypsin in HBSS for 15 minutes at room temperature. Digested tissue was washed three times with HBSS then dissociated into a single cell suspension by trituration with a glass pipette. Using a growth medium containing 42% Delbecco's modified Eagle's medium with 42% HAM F12 nutrient supplement, 10% heat inactivated horse serum, and 6% heat inactivated fetal calf serum (10/6 DME/F12), cell density was adjusted to one cortical hemisphere per 10 mL of triturated suspension. One hundred microliters of this cell suspension was pipetted into individual wells of 96-well tissue culture plates previously coated with poly-L-lysine, then stored in a humidified incubator (37°C, 3% CO<sub>2</sub>). Glial cell growth was stopped by the addition of 100 µL of 45% DME, 45% HAM F12, and 10% Horse serum (10/0 DME/F12) containing 15 µg/mL of 5-fluoro-2-deoxyuridine and 35 µg/mL of uridine, 3 days after the initial plating. Cultures were fed at 2- or 3-day intervals thereafter by replacing 100 µL of spent medium with an identical volume of fresh 10/0 DME/F12.

35

#### Experimental Protocol

Sixteen-day-old cultures were prepared for experiments by removing growth medium from each culture well and rinsing once with 250 µL of Mg<sup>++</sup>-free HBSS

-23-

containing 1.8 mM  $\text{Ca}^{++}$  and 1 g/L D-glucose (0 Mg-HBSS). Control and test agent solutions, prepared using 0 Mg-HBSS medium, were dispensed in 50  $\mu\text{L}$  aliquots into individual test wells (Total volume/well = 50  $\mu\text{L}$ ). All liquid medium preparations to this point were equilibrated with 95% oxygen, 5%  $\text{CO}_2$ . Plates were placed into a 37°C, humidified, triple-gas incubator with  $\text{O}_2$  and  $\text{CO}_2$  levels maintained at 1% and 10%, respectively. Plates were removed after 7.5 hours of oxygen deprivation and restored to normoxic conditions (20%  $\text{O}_2$ /10%  $\text{CO}_2$ , 37°C) following a 50  $\mu\text{L}$  addition to each well of appropriate control or test agent solutions containing 1.8 mM  $\text{Ca}^{++}$ , 1.6 mM  $\text{Mg}^{++}$ , and 7.0 g/L D-glucose. Final medium concentrations of 1.8 mM  $\text{Ca}^{++}$ , 0.8 mM  $\text{Mg}^{++}$ , and 4 g/L D-glucose were present during the reoxygenation period.

Medium concentrations of lactate dehydrogenase (LDH), a cytosolic enzyme normally retained by cells but released upon cell death, were determined for each well following an additional 16.5-hour normoxic exposure period. Individual 25  $\mu\text{L}$  medium specimens were collected from each well and placed into wells of a clean 96-well microtiter plate containing 225  $\mu\text{L}$  of 0.1 M  $\text{KPO}_4$  buffer (pH = 7.5 at 25°C) and 30  $\mu\text{g}$  NADH (reduced  $\alpha$ -nicotinamide adenine dinucleotide). After 10-minute incubation at 37°C, 30  $\mu\text{L}$  of 2.4 mM sodium pyruvate was added to each well and plates were gently shaken to mix solution. Plates were immediately placed into a Multiscan MCC/340 plate reader and scanned for fluorescence (excitation at 340 nm) for 1 minute at 5-second intervals. A kinetic analysis of the change in medium absorbance resulting from shifts in NADH concentrations was used, in combination with factors to correct for temperature, light path, and volume adjustments to determine medium LDH concentrations (IU/mL). Normoxic control baseline LDH levels were subtracted from both hypoxic control and test agent

-24-

values prior to determining test agent effectiveness in preventing oxygen deprivation-induced injury.

5      TABLE 3. Hypoxia-Induced Lactate Dehydrogenase Release (Cell Injury) in Neuronal/Glial Cortical Cultures

	Test Group		LDH Release		% Inh <sup>a</sup>
	Normoxic Control		74 ± 4		100%
10	Hypoxic Control		163 ± 11		0%
	CPP	100 μM	80 ± 8		93%
	TTX	3 μM	81 ± 5		92%
15	Lamotrigine	30 μM	102 ± 16		68%
		100 μM	89 ± 6		83%
	Phenytoin	30 μM	93 ± 6		78%
20		100 μM	90 ± 3		82%
	N-(2,6-dichlorophenyl)-N'-4-pyridinyl urea	30 μM	107 ± 8		62%
		100 μM	84 ± 6		88%
25	N-(2,6-dimethylphenyl)-N'-4-pyridinyl urea	30 μM	68 ± 6		106%
		100 μM	91 ± 7		81%
	N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea	30 μM	73 ± 6		101%
30		100 μM	92 ± 4		80%
	Carbamazepine	30 μM	116 ± 3		53%
		100 μM	78 ± 4		95%

LDH Release Determinations: n = 4 for each mean value.


35      <sup>a</sup> % Inh refers to the percent inhibition of the release of lactate dehydrogenase in comparison to hypoxic control cultures.

- 25 -

## CLAIMS

- 5 1. A method for treating neurodegenerative diseases or disorders which comprises administering a therapeutically effective amount of a compound having anticonvulsant properties which bind to sodium channels and modulate the channel without blocking the channel, the compounds preventing irreversible neuronal damage from conditions similar to ischemia.
2. A method for treating neurodegenerative diseases or disorders as in Claim 1 which comprises administering a therapeutically effective amount of a compound of formula

5



I

- 10 wherein A is 4-pyridinyl;  $R_1$  and  $R_2$  are independently halogen, lower alkyl, lower alkoxy, or nitro, and  $R_3$  is hydrogen, halogen, lower alkyl, lower alkoxy, or nitro, or a pharmaceutically acceptable acid addition salt thereof.

3. A method according to Claim 2 wherein the compound is administered in unit dosage form to a mammal in need of said treatment.
4. A method according to Claim 2 wherein the neurodegenerative disorder is acute brain injury.

-26-

5. A method according to Claim 2 wherein the neurodegenerative disorder is stroke.
6. A method according to Claim 2 wherein the neurodegenerative disease is Alzheimer's disease.
7. A method according to Claim 2 wherein the neurodegenerative disease is Huntington's disease.
8. A method according to Claim 2 wherein the neurodegenerative disease is Amyotrophic Lateral Sclerosis.
9. A method according to Claim 2 wherein the neurodegenerative disease is Parkinson's disease.
10. A method according to Claim 2 wherein the compound is N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea monohydrochloride or a pharmaceutically acceptable salt thereof.
11. A method according to Claim 2 wherein the compound is N-(2,3-dichlorophenyl)-N'-4-pyridinyl urea or a pharmaceutically acceptable salt thereof.
12. A method according to Claim 2 wherein an individual dose is administered in the range from about 10 mg to about 1000 mg intravenously of the compound or a pharmaceutically acceptable salt thereof is administered.
13. A method according to Claim 3 wherein an individual dose is in the range from about 50 mg to about 2000 mg parenterally or about 50 to about 5000 mg enterally of the compound or a pharmaceutically acceptable salt thereof is administered.

-27-

14. A method for treating neurodegenerative diseases or disorders as in Claim 1 which comprises administering a therapeutically effective amount of ralitoline.
15. A method for treating neurodegenerative diseases or disorders as in Claim 1 which comprises administering a therapeutically effective amount of phenytoin.
16. A method for treating neurodegenerative diseases or disorders as in Claim 1 which comprises administering a therapeutically effective amount of lamotrigine.
17. A method for treating neurodegenerative diseases or disorders as in Claim 1 which comprises administering a therapeutically effective amount of carbamazepine.
18. A method for treating neurodegenerative diseases or disorders as in Claim 1 which comprises administering a therapeutically effective amount of lidocaine.
19. A method for treating neurodegenerative diseases or disorders as in Claim 1 which comprises administering a therapeutically effective amount of tetrodotoxin.

1 / 3

FIG. 1A





FIG. 1B



2 / 3

FIG. 2












FIG. 3



3/3

FIG. 4



-  CONTROL
-  PHENYTOIN(DPH)
-  CARBAMAZETINE(CBZ)
-  LIDOCAINE(LID)
-  VERAPAMIL(VER)
-  NIMODIPINE(NIM)

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup>:</b> A61K 31/44, 31/415, 31/53, 31/55, 31/165, A61K 31/425, 31/70	<b>A3</b>	<b>(11) International Publication Number:</b> WO 94/18972 <b>(43) International Publication Date:</b> 1 September 1994 (01.09.94)
<b>(21) International Application Number:</b> PCT/US94/01788 <b>(22) International Filing Date:</b> 17 February 1994 (17.02.94)  <b>(30) Priority Data:</b> 08/023,016      25 February 1993 (25.02.93)      US  <b>(71) Applicant:</b> WARNER-LAMBERT COMPANY [US/US]; 2800 Plymouth Road, Ann Arbor, MI 48105 (US).  <b>(72) Inventors:</b> TAYLOR, Charles, Price, Jr.; 7560 Lake Shore Drive, Chelsea, MI 48118 (US). WEBER, Mark, Lawrence; 24678 Farmington Road, Farmington Hills, MI 48336 (US).  <b>(74) Agents:</b> ASHBROOK, Charles, W.; Warner-Lambert Com- pany, 2800 Plymouth Road, Ann Arbor, MI 48105 (US) et al.	<b>(81) Designated States:</b> AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>  <b>(88) Date of publication of the international search report:</b> 22 December 1994 (22.12.94)	
<b>(54) Title:</b> METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS USING N-(2,6-DISUBSTITUTED AROMATIC)-N'-PYRIDINYL UREAS AND OTHER ANTICONVULSANT COMPOUNDS  <b>(57) Abstract</b>  The instant invention is novel uses of known N-(2,6-disubstituted phenyl)-N'-3- and 4-pyridinyl ureas and pharmaceutically acceptable acid addition salts thereof. Such compounds as N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea monohydrochloride or N-(2,3-dichlorophenyl)-N'-4-pyridinyl urea are used for treating neurodegenerative disorders, perinatal asphyxia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. The instant invention is similar novel uses of known anticonvulsant compounds as riluzole, phenytoin, lamotrigine, tetrodotoxin, lidocaine, and carbamazepine.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KC	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TC	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 5 A61K31/44 A61K31/415 A61K31/53 A61K31/55 A61K31/165  
 A61K31/425 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 135 335 (WARNER-LAMBERT COMPANY) 27 March 1985 see claims 1-10 & US,A,4 629 731 (IDEM) cited in the application ---	1-13
X	EPILEPSY RES., vol.8, no.3, April 1991 pages 197 - 203 D.M.ROCK ET AL. 'Raltitoline (CI-946) and CI-953 block sustained repetitive sodium action potentials in cultered mouse spinal cord neurons and displace batrachotoxin A 20-alpha-benzoate binding in vitro' see page 202, left column, paragraph 2 --- -/--	1-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

11 October 1994

Date of mailing of the international search report

10.11.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3016

Authorized officer

Theuns, H

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. PHARMACOL. EXP. THER., vol. 255, no. 3, 1990 pages 1117 - 1122 P.J. PAUWELS ET AL. 'Neurotoxic Action of Veratridine in Rat Brain Neuronal Cultures: Mechanism of Neuroprotection by Ca <sup>++</sup> Antagonists Nonselective for Slow Ca <sup>++</sup> Channels' see abstract ---	1-13
X	BRAIN RES., vol. 528, no. 2, 1 October 1990 pages 212 - 222 D. ASHTON ET AL. 'Extracellular ions during veratridine-induced neurotoxicity in hippocampal slices: neuroprotective effects of flunarizine and tetrodotoxin' see abstract ---	1-13
X	CAN. J. ANAESTH., vol. 37, no. 7, October 1990 pages 762 - 777 R. HALL ET AL. 'Brain protection: physiological and pharmacological considerations. Part II: The pharmacology of brain protection' see page 767 see page 771 ---	1-13, 15
X	METHODS FIND. EXP. CLIN. PHARMACOL., vol. 12, no. 1, 1990 pages 17 - 22 S. N. THOKAT ET AL. 'The Protective Effect of Adenosinergic Agents, Ro 5-4864 and Carbamazepine against Hypoxic Stress-Induced Neurotoxicity in Mice' see abstract ---	1-13
X	STROKE, vol. 21, no. 11SU, November 1990 pages III-47 - III-51 P. A. BOXER ET AL. 'Comparison of Phenytoin With Noncompetitive N-Methyl-D-Aspartate Antagonists in a Model of Focal Brain Ischemia in Rat' * see abstract, last sentence * --- -/--	1-13, 15

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	DIALOG INFORMATION SERVICES, FILE 5: BIOSIS PREVIEWS, ACCESSION NUMBER 10861114 see abstract & SOC. NEUROSCI.ABSTR., vol.19, no.1-3, 1993 page 1657 M.G.VARTANIAN ET AL. 'Phenytoin and CI 953 attenuate hypoxic-ischemic brain damage in neonatal rats'	1-13
X	--- CHEMICAL ABSTRACTS, vol. 82, no. 15, 14 April 1975, Columbus, Ohio, US; abstract no. 93096s, see abstract & NEW MED. J., vol.16, no.8, 1973 pages 47 - 56 B.H.SONG 'Effects of diphenylhydantoin on the changes of ATPase activity and electrolytes induced by local cerebral cortex injury in the rabbit'	1,15
X	--- BRAIN RES., vol.546, no.2, 19 April 1991 pages 351 - 354 P.K.STANTON ET AL. 'Diphenylhydantoin protects against hypoxia-induced impairment of hippocampal synaptic transmission' see the whole document	1,15
X	--- BYULL.EKSP.BIOL.MED., vol.110, no.9, September 1990 pages 242 - 244 G.N.KRYZHANOVSKII ET AL. 'THE EFFECT OF DIPHENINE ON EXPERIMENTAL PARKINSONIAN SYNDROME' see abstract	1,15
X	--- EUR.NEUROL., vol.6, no.1-6, 1972 pages 107 - 113 M.BALDY-MOULINIER 'Cerebral Blood Flow and Membrane Ionic Pump' see the whole document	1,15
X	--- REV.MÉD.LIÈGE, vol.34, no.20, 15 October 1979 pages 839 - 845 M.CORDONNIER ET AL. 'FASCICULATIONS MALIGNES ET BÉNIGNES. A PROPOS D'UN CAS DE NEUROMYOTONIE' see page 843 --- -/--	1,15

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	J. PHARMACOL. EXP. THER., vol. 266, no. 3, September 1993 pages 1549 - 1555 R. FERN ET AL. 'Pharmacological Protection of CNS White Matter during Anoxia: Actions of Phenytoin, Carbamazepine and Diazepam' see abstract ---	1, 15
X	BRAIN RES., vol. 558, no. 1, 1991 pages 127 - 130 P. E. POTTER ET AL. 'Diphenylhydantoin attenuates hypoxia-induced release of [3H]glutamate from rat hippocampal slices' see the whole document ---	1, 15
X	EUR. J. PHARMACOL., vol. 128, no. 3, 9 September 1986 pages 255 - 257 E. MELAMED ET AL. 'Diphenylhydantoin and phenobarbital suppress the dopaminergic neurotoxicity of MPTP in mice' see abstract ---	1, 15
X	J. NEUROSURG., vol. 60, no. 3, March 1984 pages 467 - 472 L. J. WILLMORE ET AL. 'Effect of phenytoin and corticosteroids on seizures and lipid peroxidation in experimental posttraumatic epilepsy' see abstract ---	1, 15
X	EP. A, 0 427 925 (WARNER-LAMBERT COMPANY) 22 May 1991 see page 2, line 52 - page 3, line 18 ---	1, 15
X	J. CEREB. BLOOD Flow METAB., vol. 2, no. SUP1, 1982 pages S59 - S61 E. M. NEMOTO ET AL. 'Free Fatty Acids (FFA) in the Pathogenesis and Therapy of Ischemic Brain Injury' see page S59, last paragraph ---	1, 15
X	PRESSE Méd., vol. 20, no. 18, 11 May 1991 pages 841 - 845 J. C. PECHADRE ET AL. 'Prévention de l'épilepsie post-traumatique tardive par phénytoïne dans les traumatismes crâniens graves. Suivi durant 2 ans' see abstract --- -/--	1, 15

## C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BR.J.HOSP.MED., vol.35, no.5, May 1986 pages 290 - 298 A.AITKENHEAD ET AL. 'Cerebral protection' see page 295 ---	1,15
X	CHEMICAL ABSTRACTS, vol. 91, no. 13, 24 September 1979, Columbus, Ohio, US; abstract no. 102275q, see abstract & D.GUASTAMACHIO 'The effect of diphenylhydantoin and procainamide on aluminium-induced Alzheimer-type neurofibrillary tangles in rabbit brain' 1979 -----	1,15

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 94/01788

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
For further information please see annex
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

For further information please see annex.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:  
  
claim 1 partially, claims 2-13  
and claim 15.
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

Continuation of BOX I.2:

Claims searchable completely: 2-19

Claims searchable incompletely: 1

The definition of compounds by means of their pharmacological profile instead of structural parameters makes a complete search for the subject matter of claim 1 virtually impossible.

Although all claims are directed to a method of treatment of the human/animal body the search has been based on the alleged effects of the compounds.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/

## Continuation of BOX II:

1. Use of compounds of formula 1 for the manufacture of medicaments for treating neurodegenerative diseases (claim 1 partially, and claims 2-13).
2. Use of ralitoline for the manufacture of medicaments for treating neurodegenerative diseases (claim 1 partially, and claim 14).
3. Use of phenytoin for the manufacture of medicaments for treating neurodegenerative diseases (claim 1 partially, and claim 15).
4. Use of lamotrigine for the manufacture of medicaments for treating neurodegenerative diseases (claim 1 partially, and claim 16).
5. Use of carbamazepine for the manufacture of medicaments for treating neurodegenerative diseases (claim 1 partially, and claim 17).
6. Use of lidocaine for the manufacture of medicaments for treating neurodegenerative diseases (claim 1 partially, and claim 18).
7. Use of tetrodotoxin for the manufacture of medicaments for treating neurodegenerative diseases (claim 1 partially, and claim 19).

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/01788

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0135335	27-03-85	AU-B- 561092	30-04-87
		AU-A- 3142684	28-02-85
		CA-A- 1246084	06-12-88
		JP-B- 6025113	06-04-94
		JP-A- 60058962	05-04-85
		US-A- 4629731	16-12-86
		US-A- 4962116	09-10-90
US-A-4629731	16-12-86	US-A- 4962116	09-10-90
		AU-B- 561092	30-04-87
		AU-A- 3142684	28-02-85
		CA-A- 1246084	06-12-88
		EP-A, B 0135335	27-03-85
		JP-B- 6025113	06-04-94
		JP-A- 60058962	05-04-85
EP-A-0427925	22-05-91	AU-B- 624262	04-06-92
		AU-A- 6083990	14-02-91
		CA-A- 2022842	11-02-91
		JP-A- 3141263	17-06-91

Form PCT/ISA/210 (patent family annex) (July 1992)